New Personalized Cancer Therapies Undergo Extensive Clinical Study
A new £9 million clinical study led by the Francis Crick Institute is set to explore personalized cancer therapies over four years. The project will analyze biomarkers from 3,000 patient samples to evaluate the effectiveness of immunotherapy for various cancers. This initiative, backed by a larger £118 million funding package, aims to revolutionize cancer treatment and enhance the UK's position in the life sciences sector.
A large-scale clinical study led by the Francis Crick Institute and involving five NHS trusts, charities, and bioscience companies is set to evaluate new personalized cancer therapies.
This £9 million, four-year partnership aims to explore innovative immunotherapy treatments and advanced detection methods for cancer.
Backed by the Department for Science, Innovation and Technology as part of a broader £118 million initiative, the project seeks to identify biomarkers from the tumors and blood samples of 3,000 cancer patients to determine the effectiveness of immunotherapy, especially for melanoma, kidney cancer, bladder cancer, and triple-negative breast cancer.
Immunotherapy, which leverages the immune system to attack tumors, offers a promising alternative to traditional cancer treatments.
Led by Prof. Samra Turajlic, the project includes collaborations with institutions like the Royal Marsden, Barts Cancer Institute, and Cambridge University Hospitals.
This effort is part of a national push to advance cancer research and technology, driven by the potential to significantly improve patient outcomes and impact the UK’s health and economic sectors.
This £9 million, four-year partnership aims to explore innovative immunotherapy treatments and advanced detection methods for cancer.
Backed by the Department for Science, Innovation and Technology as part of a broader £118 million initiative, the project seeks to identify biomarkers from the tumors and blood samples of 3,000 cancer patients to determine the effectiveness of immunotherapy, especially for melanoma, kidney cancer, bladder cancer, and triple-negative breast cancer.
Immunotherapy, which leverages the immune system to attack tumors, offers a promising alternative to traditional cancer treatments.
Led by Prof. Samra Turajlic, the project includes collaborations with institutions like the Royal Marsden, Barts Cancer Institute, and Cambridge University Hospitals.
This effort is part of a national push to advance cancer research and technology, driven by the potential to significantly improve patient outcomes and impact the UK’s health and economic sectors.
